CellCept Has Positive Results in Phase III Lupus Nephritis Trial
Links shared publicly online about this topic
CellCept Has Positive Results in Phase III Lupus Nephritis Trial | Lupus Research Institute
lupusresearchinstitute.org — “The Lupus Research Institute (LRI) provides LupusResearchInstitute.org to help scientists and physicians, patients, and their families champion novel and innovative lupus research. On the homepage you will find information about lupus and the LRI as well as lupus research and news.” View full resource at lupusresearchinstitute.org
Most Recently Shared on June 3, 2010 at 7:59 pm By:
CellCept® Has Positive Results in Phase III Lupus Nephritis Trial - Read more at http://ht.ly/1TL8g
Galenica.com - CellCept reaches positive results in Phase III trial in Lupus Nephritis
galenica.com — “Vifor Pharma, the pharma business sector of the Galenica Group, and Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the maintenance phase of the Aspreva Lupus Man-agement Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche's CellCept (mycophenolate mofetil) versus azathioprine (AZA) in de-laying treatment failure in patients with Lupus Nephritis (LN). ALMS is one of the largest stud-ies ever conducted in LN.” View full resource at galenica.com
Most Recently Shared on September 22, 2010 at 4:12 pm By:
Lupus Doctor Doctor, Internist, Rheumatologist, and Physician
ALMSTrialCellCept vs AZA rx in patients who responded to CYT or AZA inductionMMF superior to AZA in delaying rx failure http://bit.ly/9f1pD0
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
LRI
The world's leading nonprofit singularly dedicated to novel research in lupus.
-
Lupus Doctor
Michael Belmont, MD - Medical Director, NYU - Hospital for Joint Diseases, Associate Professor of Medicine, Rheumatologist
Advertisement
